The monoclonal antibody trastuzumab was chosen as a model antibodyfor assessing conjugation of sar–dbm and dfo–dbm: trastuzumabtargets the human epidermal growth factor receptor 2 (HER2) and iswidely used for treatment of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.